Pacific Biosciences Of California (PACB) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.11% |
| Dec 31, 2025 | -5.98% |
| Sep 30, 2025 | -0.99% |
| Jun 30, 2025 | -4.31% |
| Mar 31, 2025 | -20.91% |
| Dec 31, 2024 | -11.01% |
| Sep 30, 2024 | -21.37% |
| Jun 30, 2024 | -25.31% |
| Mar 31, 2024 | -24.49% |
| Dec 31, 2023 | -24.84% |
| Sep 30, 2023 | -35.68% |
| Jun 30, 2023 | -23.55% |
| Mar 31, 2023 | -38.21% |
| Dec 31, 2022 | -24.56% |
| Sep 30, 2022 | -28.73% |
| Jun 30, 2022 | -36.44% |
| Mar 31, 2022 | -36.51% |
| Dec 31, 2021 | -19.70% |
| Jun 30, 2021 | 3.61% |
| Mar 31, 2021 | -2.65% |
| Dec 31, 2020 | -82.01% |
| Sep 30, 2020 | -2.46% |
| Jun 30, 2020 | -25.99% |
| Mar 31, 2020 | 38.80% |
| Dec 31, 2019 | -3.43% |
| Sep 30, 2019 | -22.59% |
| Jun 30, 2019 | -5.21% |
| Mar 31, 2019 | -9.26% |
| Dec 31, 2018 | -5.43% |
| Sep 30, 2018 | -22.49% |
| Jun 30, 2018 | 2.44% |
| Mar 31, 2018 | -1.33% |
| Dec 31, 2017 | -2.08% |
| Sep 30, 2017 | -0.21% |
| Jun 30, 2017 | 11.51% |
| Mar 31, 2017 | 0.78% |
| Dec 31, 2016 | 2.67% |
| Sep 30, 2016 | 7.82% |
| Jun 30, 2016 | 9.37% |
| Mar 31, 2016 | 9.54% |
| Dec 31, 2015 | 55.08% |
| Sep 30, 2015 | 13.91% |